Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 15, 2010 | SVP & General Counsel | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,000 | -- | 20,000 | |
| Jun 15, 2010 | SVP, HR & Leadership Devt | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,000 | -- | 20,000 | |
| Nov 04, 2009 | Director | Open market or private purchase of non-derivative or derivative security | Form 4 | 20,000 | $4.13 | 20,000 | |
| Jun 10, 2008 | Chief Scientific Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 20,000 | -- | 20,000 | |
| Apr 24, 2008 | Senior VP, Drug Development | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | $0.64 | 62,116 | |
| Apr 24, 2008 | Senior VP, Drug Development | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | -- | 4,924 | |
| Jan 02, 2008 | Director, President and CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | $0.64 | 68,736 | |
| Jan 02, 2008 | Director, President and CEO | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,000 | -- | 89,930 | |
| Dec 02, 2008 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,098 | $0.64 | 56,547 | |
| Dec 02, 2008 | Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 20,098 | -- | -- |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.